Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00659178
Recruitment Status : Completed
First Posted : April 16, 2008
Last Update Posted : July 21, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Tracking Information
First Submitted Date  ICMJE April 10, 2008
First Posted Date  ICMJE April 16, 2008
Last Update Posted Date July 21, 2017
Actual Study Start Date  ICMJE June 18, 2008
Actual Primary Completion Date February 18, 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 18, 2008)
Safety and tolerability of SB-485232/Doxil combination therapy [ Time Frame: 16 weeks ]
Original Primary Outcome Measures  ICMJE
 (submitted: April 10, 2008)
Safety and tolerability of SB-485232/Doxil combination therapy [ Time Frame: for 16 weeks ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 18, 2008)
  • Biological activity of SB-485232/Doxil combination therapy [ Time Frame: 16 weeks ]
  • Pharmacokinetic parameters for SB-485232 and Doxil: AUC(0-t), Cmax, and Cmin [ Time Frame: 16 weeks ]
  • Pharmacodynamic biomarker responses [ Time Frame: 16 weeks ]
  • Immunogenicity (anti-SB-485232 and anti-PEG antibodies) [ Time Frame: 16 weeks ]
  • Anti-tumor activity (Radiographic tumor assessments and serum CA-125 levels) [ Time Frame: 16 weeks ]
Original Secondary Outcome Measures  ICMJE
 (submitted: April 10, 2008)
  • Biological activity of SB-485232/Doxil combination therapy [ Time Frame: for 16 weeks ]
  • Pharmacokinetic parameters for SB-485232 and Doxil: AUC(0-t), Cmax, and Cmin
  • Pharmacodynamic biomarker responses
  • Immunogenicity (anti-SB-485232 and anti-PEG antibodies)
  • Anti-tumor activity (Radiographic tumor assessments and serum CA-125 levels)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Official Title  ICMJE A Phase I, Dose Escalation Study to Assess the Safety & Biological Activity of Interleukin 18 (SB-485232) Administered by IV Infusion in Combination With Pegylated Liposomal Doxorubicin (Doxil) in Advanced Stage Epithelial Ovarian Cancer
Brief Summary The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in patients with epithelial ovarian cancer. This study will use a standard treatment regimen of pegylated liposomal doxorubicin (Doxil) in combination with rising doses of SB-485232. The dose selected from this study will be used in a future studies to evaluate the efficacy of this combination.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Neoplasms, Ovarian
Intervention  ICMJE Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Other Names:
  • SB-485232 (interleukin 18)
  • pegylated liposomal doxorubicin
Study Arms  ICMJE Experimental: SB-485232 plus pegylated liposomal doxorubicin
Subjects will receive one dose of pegylated liposomal doxorubicin on Day 1 plus two doses of SB-485232 on Day 3 and Day 9 in each cycle.
Intervention: Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 22, 2009)
15
Original Estimated Enrollment  ICMJE
 (submitted: April 10, 2008)
18
Actual Study Completion Date  ICMJE February 18, 2011
Actual Primary Completion Date February 18, 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Female, age ≥18 years of age;
  2. Histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma;
  3. Candidate to receive pegylated liposomal doxorubicin for treatment of advanced stage ovarian cancer as per standard of care and in the opinion of the treating principal investigator;
  4. Measurable lesion(s) according to RECIST v1.0;
  5. ECOG performance status of 0, 1 or 2;
  6. Predicted life expectancy of ≥4 months
  7. No chemotherapy, immunotherapy, hormonal therapy, or biological therapy for cancer, radiotherapy, or surgical procedures (except for minor surgical procedures) within four weeks before beginning treatment with SB-485232 (six weeks for nitrosoureas and mitomycin C). Subjects must have recovered from toxicities (incurred as a result of previous therapy) sufficiently to be entered into a Phase I study;
  8. Disease-free period of at least five years from prior malignancies (except for curatively treated basal and squamous cell carcinomas of the skin and/or carcinoma of the cervix in situ);
  9. Left ventricular ejection fraction (LVEF) ≥50 % as determined by MUGA scan;
  10. A signed and dated written informed consent form is obtained from the subject;
  11. The subject is able to understand and comply with protocol requirements, timetables, instructions and protocol-stated restrictions;
  12. The subject is likely to maintain good venous blood access for PK and PD sampling throughout the study;
  13. A female is eligible to enter and participate in the study if she is of: non-childbearing potential (i.e., physiologically incapable of becoming pregnant) or, childbearing potential, has a negative serum pregnancy test at the screening visit, and agrees to one of several GSK acceptable contraceptive methods;
  14. Adequate organ function defined as: ANC ≥1.5 x 10^9/L; hemoglobin ≥9 g/dL (after transfusion if needed); platelets ≥75 x 10^9/L.

Exclusion Criteria:

  1. Significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal or autoimmune conditions that in the opinion of the investigator and/or GSK medical monitor, places the subject at an unacceptable risk as participant in this trial;
  2. Any severe concurrent disease or condition, including significant active autoimmune diseases such as rheumatoid arthritis, which in the judgment of the principal investigator, would make the subject inappropriate for study participation;
  3. History of myocardial infarction, unstable angina, or acute coronary syndrome within the past six months;
  4. The subject has a history of hypersensitivity reactions to a conventional formulation of doxorubicin HCl or the components of pegylated liposomal doxorubicin;
  5. The subject has a history of receiving a total cumulative dosage of doxorubicin HCl exceeding the currently recommended limit of 550 mg/m^2 or will exceed the 550 mg/m^2 dosage limit during the course of the current study. A subject will also be excluded if they received a lower cumulative dosage of doxorubicin HCl (i.e., 400 mg/m^2) and also had prior radiotherapy to the mediastinal area or concomitant therapy with other potentially cardiotoxic agents such as cyclophosphamide. Prior use of other anthracyclines or anthracenediones should be included in calculations of total cumulative doxorubicin HCl dosage;
  6. Women who are pregnant or are breast-feeding;
  7. Corrected QT interval (QTc) ≥480 msec (average of three measurements to be made at screening);
  8. The subject has diabetes mellitus with poor glycemic control;
  9. The subject has a history of human immunodeficiency virus (HIV) or other immunodeficiency disease;
  10. The subject has positive Hepatitis B surface antigen;
  11. The subject has a history of a severe infusion-related reaction following treatment with pegylated liposomal doxorubicin as described in the protocol;
  12. The subject has an acute infection or severe or uncontrolled infections requiring systemic antibiotic therapy;
  13. Any serious medical or psychiatric disorder that would interfere with subject safety or informed consent;
  14. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol;
  15. Known leptomeningeal disease or evidence of prior or current metastatic brain disease. Routine screening with central nervous system (CNS) imaging studies (CT or MRI) is required only if clinically indicated;
  16. Receiving concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy;
  17. Oral corticosteroids within 14 days of study entry;
  18. History of ventricular arrhythmias requiring drug or device therapy;
  19. Any investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of SB-485232;
  20. The subject has active signs of a bowel obstruction.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00659178
Other Study ID Numbers  ICMJE ILI108621
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Responsible Party GlaxoSmithKline
Study Sponsor  ICMJE GlaxoSmithKline
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: GSK Clinical Trials GlaxoSmithKline
PRS Account GlaxoSmithKline
Verification Date July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP